Request for Covid-19 Impact Assessment of this Report
The United States Neuroblastoma Chemotherapy Drugs market is expected at value of US$ million in 2021 and grow at approximately % CAGR during forecast period 2022-2028. China constitutes a % market for the global Neuroblastoma Chemotherapy Drugs market, reaching US$ million by the year 2028. As for the Europe Neuroblastoma Chemotherapy Drugs landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period 2022-2028. In APAC, the growth rates of other notable markets (Japan and South Korea) are projected to be at % and % respectively for the next 6-year period.
Global main Neuroblastoma Chemotherapy Drugs players cover Baxter Healthcare, Ingenus Pharmaceuticals, ANI Pharmaceuticals, and Teva Pharmaceuticals, etc. In terms of revenue, the global largest two companies occupy a share nearly % in 2021.
This report presents a comprehensive overview, market shares, and growth opportunities of Neuroblastoma Chemotherapy Drugs market by product type, application, key manufacturers and key regions and countries.
Segmentation by type: breakdown data from 2017 to 2022, in Section 2.3; and forecast to 2028 in section 12.6
Cyclophosphamide
Cisplatin or Carboplatin
Vincristine
Doxorubicin (Adriamycin)
Etoposide
Other
Segmentation by application: breakdown data from 2017 to 2022, in Section 2.4; and forecast to 2028 in section 12.7.
Hospital
Clinic
Other
This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The report also presents the market competition landscape and a corresponding detailed analysis of the prominent manufacturers in this market, include
Baxter Healthcare
Ingenus Pharmaceuticals
ANI Pharmaceuticals
Teva Pharmaceuticals
Qilu Pharmaceutical
Pfizer
Hikma Pharmaceuticals
Fresenius Kabi
Accord Healthcare
Viatris
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Neuroblastoma Chemotherapy Drugs Annual Sales 2017-2028
2.1.2 World Current & Future Analysis for Neuroblastoma Chemotherapy Drugs by Geographic Region, 2017, 2022 & 2028
2.1.3 World Current & Future Analysis for Neuroblastoma Chemotherapy Drugs by Country/Region, 2017, 2022 & 2028
2.2 Neuroblastoma Chemotherapy Drugs Segment by Type
2.2.1 Cyclophosphamide
2.2.2 Cisplatin or Carboplatin
2.2.3 Vincristine
2.2.4 Doxorubicin (Adriamycin)
2.2.5 Etoposide
2.2.6 Other
2.3 Neuroblastoma Chemotherapy Drugs Sales by Type
2.3.1 Global Neuroblastoma Chemotherapy Drugs Sales Market Share by Type (2017-2022)
2.3.2 Global Neuroblastoma Chemotherapy Drugs Revenue and Market Share by Type (2017-2022)
2.3.3 Global Neuroblastoma Chemotherapy Drugs Sale Price by Type (2017-2022)
2.4 Neuroblastoma Chemotherapy Drugs Segment by Application
2.4.1 Hospital
2.4.2 Clinic
2.4.3 Other
2.5 Neuroblastoma Chemotherapy Drugs Sales by Application
2.5.1 Global Neuroblastoma Chemotherapy Drugs Sale Market Share by Application (2017-2022)
2.5.2 Global Neuroblastoma Chemotherapy Drugs Revenue and Market Share by Application (2017-2022)
2.5.3 Global Neuroblastoma Chemotherapy Drugs Sale Price by Application (2017-2022)
3 Global Neuroblastoma Chemotherapy Drugs by Company
3.1 Global Neuroblastoma Chemotherapy Drugs Breakdown Data by Company
3.1.1 Global Neuroblastoma Chemotherapy Drugs Annual Sales by Company (2020-2022)
3.1.2 Global Neuroblastoma Chemotherapy Drugs Sales Market Share by Company (2020-2022)
3.2 Global Neuroblastoma Chemotherapy Drugs Annual Revenue by Company (2020-2022)
3.2.1 Global Neuroblastoma Chemotherapy Drugs Revenue by Company (2020-2022)
3.2.2 Global Neuroblastoma Chemotherapy Drugs Revenue Market Share by Company (2020-2022)
3.3 Global Neuroblastoma Chemotherapy Drugs Sale Price by Company
3.4 Key Manufacturers Neuroblastoma Chemotherapy Drugs Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Neuroblastoma Chemotherapy Drugs Product Location Distribution
3.4.2 Players Neuroblastoma Chemotherapy Drugs Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for Neuroblastoma Chemotherapy Drugs by Geographic Region
4.1 World Historic Neuroblastoma Chemotherapy Drugs Market Size by Geographic Region (2017-2022)
4.1.1 Global Neuroblastoma Chemotherapy Drugs Annual Sales by Geographic Region (2017-2022)
4.1.2 Global Neuroblastoma Chemotherapy Drugs Annual Revenue by Geographic Region
4.2 World Historic Neuroblastoma Chemotherapy Drugs Market Size by Country/Region (2017-2022)
4.2.1 Global Neuroblastoma Chemotherapy Drugs Annual Sales by Country/Region (2017-2022)
4.2.2 Global Neuroblastoma Chemotherapy Drugs Annual Revenue by Country/Region
4.3 Americas Neuroblastoma Chemotherapy Drugs Sales Growth
4.4 APAC Neuroblastoma Chemotherapy Drugs Sales Growth
4.5 Europe Neuroblastoma Chemotherapy Drugs Sales Growth
4.6 Middle East & Africa Neuroblastoma Chemotherapy Drugs Sales Growth
5 Americas
5.1 Americas Neuroblastoma Chemotherapy Drugs Sales by Country
5.1.1 Americas Neuroblastoma Chemotherapy Drugs Sales by Country (2017-2022)
5.1.2 Americas Neuroblastoma Chemotherapy Drugs Revenue by Country (2017-2022)
5.2 Americas Neuroblastoma Chemotherapy Drugs Sales by Type
5.3 Americas Neuroblastoma Chemotherapy Drugs Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Neuroblastoma Chemotherapy Drugs Sales by Region
6.1.1 APAC Neuroblastoma Chemotherapy Drugs Sales by Region (2017-2022)
6.1.2 APAC Neuroblastoma Chemotherapy Drugs Revenue by Region (2017-2022)
6.2 APAC Neuroblastoma Chemotherapy Drugs Sales by Type
6.3 APAC Neuroblastoma Chemotherapy Drugs Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Neuroblastoma Chemotherapy Drugs by Country
7.1.1 Europe Neuroblastoma Chemotherapy Drugs Sales by Country (2017-2022)
7.1.2 Europe Neuroblastoma Chemotherapy Drugs Revenue by Country (2017-2022)
7.2 Europe Neuroblastoma Chemotherapy Drugs Sales by Type
7.3 Europe Neuroblastoma Chemotherapy Drugs Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Neuroblastoma Chemotherapy Drugs by Country
8.1.1 Middle East & Africa Neuroblastoma Chemotherapy Drugs Sales by Country (2017-2022)
8.1.2 Middle East & Africa Neuroblastoma Chemotherapy Drugs Revenue by Country (2017-2022)
8.2 Middle East & Africa Neuroblastoma Chemotherapy Drugs Sales by Type
8.3 Middle East & Africa Neuroblastoma Chemotherapy Drugs Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Neuroblastoma Chemotherapy Drugs
10.3 Manufacturing Process Analysis of Neuroblastoma Chemotherapy Drugs
10.4 Industry Chain Structure of Neuroblastoma Chemotherapy Drugs
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Neuroblastoma Chemotherapy Drugs Distributors
11.3 Neuroblastoma Chemotherapy Drugs Customer
12 World Forecast Review for Neuroblastoma Chemotherapy Drugs by Geographic Region
12.1 Global Neuroblastoma Chemotherapy Drugs Market Size Forecast by Region
12.1.1 Global Neuroblastoma Chemotherapy Drugs Forecast by Region (2023-2028)
12.1.2 Global Neuroblastoma Chemotherapy Drugs Annual Revenue Forecast by Region (2023-2028)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Neuroblastoma Chemotherapy Drugs Forecast by Type
12.7 Global Neuroblastoma Chemotherapy Drugs Forecast by Application
13 Key Players Analysis
13.1 Baxter Healthcare
13.1.1 Baxter Healthcare Company Information
13.1.2 Baxter Healthcare Neuroblastoma Chemotherapy Drugs Product Offered
13.1.3 Baxter Healthcare Neuroblastoma Chemotherapy Drugs Sales, Revenue, Price and Gross Margin (2020-2022)
13.1.4 Baxter Healthcare Main Business Overview
13.1.5 Baxter Healthcare Latest Developments
13.2 Ingenus Pharmaceuticals
13.2.1 Ingenus Pharmaceuticals Company Information
13.2.2 Ingenus Pharmaceuticals Neuroblastoma Chemotherapy Drugs Product Offered
13.2.3 Ingenus Pharmaceuticals Neuroblastoma Chemotherapy Drugs Sales, Revenue, Price and Gross Margin (2020-2022)
13.2.4 Ingenus Pharmaceuticals Main Business Overview
13.2.5 Ingenus Pharmaceuticals Latest Developments
13.3 ANI Pharmaceuticals
13.3.1 ANI Pharmaceuticals Company Information
13.3.2 ANI Pharmaceuticals Neuroblastoma Chemotherapy Drugs Product Offered
13.3.3 ANI Pharmaceuticals Neuroblastoma Chemotherapy Drugs Sales, Revenue, Price and Gross Margin (2020-2022)
13.3.4 ANI Pharmaceuticals Main Business Overview
13.3.5 ANI Pharmaceuticals Latest Developments
13.4 Teva Pharmaceuticals
13.4.1 Teva Pharmaceuticals Company Information
13.4.2 Teva Pharmaceuticals Neuroblastoma Chemotherapy Drugs Product Offered
13.4.3 Teva Pharmaceuticals Neuroblastoma Chemotherapy Drugs Sales, Revenue, Price and Gross Margin (2020-2022)
13.4.4 Teva Pharmaceuticals Main Business Overview
13.4.5 Teva Pharmaceuticals Latest Developments
13.5 Qilu Pharmaceutical
13.5.1 Qilu Pharmaceutical Company Information
13.5.2 Qilu Pharmaceutical Neuroblastoma Chemotherapy Drugs Product Offered
13.5.3 Qilu Pharmaceutical Neuroblastoma Chemotherapy Drugs Sales, Revenue, Price and Gross Margin (2020-2022)
13.5.4 Qilu Pharmaceutical Main Business Overview
13.5.5 Qilu Pharmaceutical Latest Developments
13.6 Pfizer
13.6.1 Pfizer Company Information
13.6.2 Pfizer Neuroblastoma Chemotherapy Drugs Product Offered
13.6.3 Pfizer Neuroblastoma Chemotherapy Drugs Sales, Revenue, Price and Gross Margin (2020-2022)
13.6.4 Pfizer Main Business Overview
13.6.5 Pfizer Latest Developments
13.7 Hikma Pharmaceuticals
13.7.1 Hikma Pharmaceuticals Company Information
13.7.2 Hikma Pharmaceuticals Neuroblastoma Chemotherapy Drugs Product Offered
13.7.3 Hikma Pharmaceuticals Neuroblastoma Chemotherapy Drugs Sales, Revenue, Price and Gross Margin (2020-2022)
13.7.4 Hikma Pharmaceuticals Main Business Overview
13.7.5 Hikma Pharmaceuticals Latest Developments
13.8 Fresenius Kabi
13.8.1 Fresenius Kabi Company Information
13.8.2 Fresenius Kabi Neuroblastoma Chemotherapy Drugs Product Offered
13.8.3 Fresenius Kabi Neuroblastoma Chemotherapy Drugs Sales, Revenue, Price and Gross Margin (2020-2022)
13.8.4 Fresenius Kabi Main Business Overview
13.8.5 Fresenius Kabi Latest Developments
13.9 Accord Healthcare
13.9.1 Accord Healthcare Company Information
13.9.2 Accord Healthcare Neuroblastoma Chemotherapy Drugs Product Offered
13.9.3 Accord Healthcare Neuroblastoma Chemotherapy Drugs Sales, Revenue, Price and Gross Margin (2020-2022)
13.9.4 Accord Healthcare Main Business Overview
13.9.5 Accord Healthcare Latest Developments
13.10 Viatris
13.10.1 Viatris Company Information
13.10.2 Viatris Neuroblastoma Chemotherapy Drugs Product Offered
13.10.3 Viatris Neuroblastoma Chemotherapy Drugs Sales, Revenue, Price and Gross Margin (2020-2022)
13.10.4 Viatris Main Business Overview
13.10.5 Viatris Latest Developments
14 Research Findings and Conclusion
Table 1. Neuroblastoma Chemotherapy Drugs Annual Sales CAGR by Geographic Region (2017, 2022 & 2028) & ($ millions)
Table 2. Neuroblastoma Chemotherapy Drugs Annual Sales CAGR by Country/Region (2017, 2022 & 2028) & ($ millions)
Table 3. Major Players of Cyclophosphamide
Table 4. Major Players of Cisplatin or Carboplatin
Table 5. Major Players of Vincristine
Table 6. Major Players of Doxorubicin (Adriamycin)
Table 7. Major Players of Etoposide
Table 8. Major Players of Other
Table 9. Global Neuroblastoma Chemotherapy Drugs Sales by Type (2017-2022) & (K Units)
Table 10. Global Neuroblastoma Chemotherapy Drugs Sales Market Share by Type (2017-2022)
Table 11. Global Neuroblastoma Chemotherapy Drugs Revenue by Type (2017-2022) & ($ million)
Table 12. Global Neuroblastoma Chemotherapy Drugs Revenue Market Share by Type (2017-2022)
Table 13. Global Neuroblastoma Chemotherapy Drugs Sale Price by Type (2017-2022) & (US$/Unit)
Table 14. Global Neuroblastoma Chemotherapy Drugs Sales by Application (2017-2022) & (K Units)
Table 15. Global Neuroblastoma Chemotherapy Drugs Sales Market Share by Application (2017-2022)
Table 16. Global Neuroblastoma Chemotherapy Drugs Revenue by Application (2017-2022)
Table 17. Global Neuroblastoma Chemotherapy Drugs Revenue Market Share by Application (2017-2022)
Table 18. Global Neuroblastoma Chemotherapy Drugs Sale Price by Application (2017-2022) & (US$/Unit)
Table 19. Global Neuroblastoma Chemotherapy Drugs Sales by Company (2020-2022) & (K Units)
Table 20. Global Neuroblastoma Chemotherapy Drugs Sales Market Share by Company (2020-2022)
Table 21. Global Neuroblastoma Chemotherapy Drugs Revenue by Company (2020-2022) ($ Millions)
Table 22. Global Neuroblastoma Chemotherapy Drugs Revenue Market Share by Company (2020-2022)
Table 23. Global Neuroblastoma Chemotherapy Drugs Sale Price by Company (2020-2022) & (US$/Unit)
Table 24. Key Manufacturers Neuroblastoma Chemotherapy Drugs Producing Area Distribution and Sales Area
Table 25. Players Neuroblastoma Chemotherapy Drugs Products Offered
Table 26. Neuroblastoma Chemotherapy Drugs Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
Table 27. New Products and Potential Entrants
Table 28. Mergers & Acquisitions, Expansion
Table 29. Global Neuroblastoma Chemotherapy Drugs Sales by Geographic Region (2017-2022) & (K Units)
Table 30. Global Neuroblastoma Chemotherapy Drugs Sales Market Share Geographic Region (2017-2022)
Table 31. Global Neuroblastoma Chemotherapy Drugs Revenue by Geographic Region (2017-2022) & ($ millions)
Table 32. Global Neuroblastoma Chemotherapy Drugs Revenue Market Share by Geographic Region (2017-2022)
Table 33. Global Neuroblastoma Chemotherapy Drugs Sales by Country/Region (2017-2022) & (K Units)
Table 34. Global Neuroblastoma Chemotherapy Drugs Sales Market Share by Country/Region (2017-2022)
Table 35. Global Neuroblastoma Chemotherapy Drugs Revenue by Country/Region (2017-2022) & ($ millions)
Table 36. Global Neuroblastoma Chemotherapy Drugs Revenue Market Share by Country/Region (2017-2022)
Table 37. Americas Neuroblastoma Chemotherapy Drugs Sales by Country (2017-2022) & (K Units)
Table 38. Americas Neuroblastoma Chemotherapy Drugs Sales Market Share by Country (2017-2022)
Table 39. Americas Neuroblastoma Chemotherapy Drugs Revenue by Country (2017-2022) & ($ Millions)
Table 40. Americas Neuroblastoma Chemotherapy Drugs Revenue Market Share by Country (2017-2022)
Table 41. Americas Neuroblastoma Chemotherapy Drugs Sales by Type (2017-2022) & (K Units)
Table 42. Americas Neuroblastoma Chemotherapy Drugs Sales Market Share by Type (2017-2022)
Table 43. Americas Neuroblastoma Chemotherapy Drugs Sales by Application (2017-2022) & (K Units)
Table 44. Americas Neuroblastoma Chemotherapy Drugs Sales Market Share by Application (2017-2022)
Table 45. APAC Neuroblastoma Chemotherapy Drugs Sales by Region (2017-2022) & (K Units)
Table 46. APAC Neuroblastoma Chemotherapy Drugs Sales Market Share by Region (2017-2022)
Table 47. APAC Neuroblastoma Chemotherapy Drugs Revenue by Region (2017-2022) & ($ Millions)
Table 48. APAC Neuroblastoma Chemotherapy Drugs Revenue Market Share by Region (2017-2022)
Table 49. APAC Neuroblastoma Chemotherapy Drugs Sales by Type (2017-2022) & (K Units)
Table 50. APAC Neuroblastoma Chemotherapy Drugs Sales Market Share by Type (2017-2022)
Table 51. APAC Neuroblastoma Chemotherapy Drugs Sales by Application (2017-2022) & (K Units)
Table 52. APAC Neuroblastoma Chemotherapy Drugs Sales Market Share by Application (2017-2022)
Table 53. Europe Neuroblastoma Chemotherapy Drugs Sales by Country (2017-2022) & (K Units)
Table 54. Europe Neuroblastoma Chemotherapy Drugs Sales Market Share by Country (2017-2022)
Table 55. Europe Neuroblastoma Chemotherapy Drugs Revenue by Country (2017-2022) & ($ Millions)
Table 56. Europe Neuroblastoma Chemotherapy Drugs Revenue Market Share by Country (2017-2022)
Table 57. Europe Neuroblastoma Chemotherapy Drugs Sales by Type (2017-2022) & (K Units)
Table 58. Europe Neuroblastoma Chemotherapy Drugs Sales Market Share by Type (2017-2022)
Table 59. Europe Neuroblastoma Chemotherapy Drugs Sales by Application (2017-2022) & (K Units)
Table 60. Europe Neuroblastoma Chemotherapy Drugs Sales Market Share by Application (2017-2022)
Table 61. Middle East & Africa Neuroblastoma Chemotherapy Drugs Sales by Country (2017-2022) & (K Units)
Table 62. Middle East & Africa Neuroblastoma Chemotherapy Drugs Sales Market Share by Country (2017-2022)
Table 63. Middle East & Africa Neuroblastoma Chemotherapy Drugs Revenue by Country (2017-2022) & ($ Millions)
Table 64. Middle East & Africa Neuroblastoma Chemotherapy Drugs Revenue Market Share by Country (2017-2022)
Table 65. Middle East & Africa Neuroblastoma Chemotherapy Drugs Sales by Type (2017-2022) & (K Units)
Table 66. Middle East & Africa Neuroblastoma Chemotherapy Drugs Sales Market Share by Type (2017-2022)
Table 67. Middle East & Africa Neuroblastoma Chemotherapy Drugs Sales by Application (2017-2022) & (K Units)
Table 68. Middle East & Africa Neuroblastoma Chemotherapy Drugs Sales Market Share by Application (2017-2022)
Table 69. Key Market Drivers & Growth Opportunities of Neuroblastoma Chemotherapy Drugs
Table 70. Key Market Challenges & Risks of Neuroblastoma Chemotherapy Drugs
Table 71. Key Industry Trends of Neuroblastoma Chemotherapy Drugs
Table 72. Neuroblastoma Chemotherapy Drugs Raw Material
Table 73. Key Suppliers of Raw Materials
Table 74. Neuroblastoma Chemotherapy Drugs Distributors List
Table 75. Neuroblastoma Chemotherapy Drugs Customer List
Table 76. Global Neuroblastoma Chemotherapy Drugs Sales Forecast by Region (2023-2028) & (K Units)
Table 77. Global Neuroblastoma Chemotherapy Drugs Sales Market Forecast by Region
Table 78. Global Neuroblastoma Chemotherapy Drugs Revenue Forecast by Region (2023-2028) & ($ millions)
Table 79. Global Neuroblastoma Chemotherapy Drugs Revenue Market Share Forecast by Region (2023-2028)
Table 80. Americas Neuroblastoma Chemotherapy Drugs Sales Forecast by Country (2023-2028) & (K Units)
Table 81. Americas Neuroblastoma Chemotherapy Drugs Revenue Forecast by Country (2023-2028) & ($ millions)
Table 82. APAC Neuroblastoma Chemotherapy Drugs Sales Forecast by Region (2023-2028) & (K Units)
Table 83. APAC Neuroblastoma Chemotherapy Drugs Revenue Forecast by Region (2023-2028) & ($ millions)
Table 84. Europe Neuroblastoma Chemotherapy Drugs Sales Forecast by Country (2023-2028) & (K Units)
Table 85. Europe Neuroblastoma Chemotherapy Drugs Revenue Forecast by Country (2023-2028) & ($ millions)
Table 86. Middle East & Africa Neuroblastoma Chemotherapy Drugs Sales Forecast by Country (2023-2028) & (K Units)
Table 87. Middle East & Africa Neuroblastoma Chemotherapy Drugs Revenue Forecast by Country (2023-2028) & ($ millions)
Table 88. Global Neuroblastoma Chemotherapy Drugs Sales Forecast by Type (2023-2028) & (K Units)
Table 89. Global Neuroblastoma Chemotherapy Drugs Sales Market Share Forecast by Type (2023-2028)
Table 90. Global Neuroblastoma Chemotherapy Drugs Revenue Forecast by Type (2023-2028) & ($ Millions)
Table 91. Global Neuroblastoma Chemotherapy Drugs Revenue Market Share Forecast by Type (2023-2028)
Table 92. Global Neuroblastoma Chemotherapy Drugs Sales Forecast by Application (2023-2028) & (K Units)
Table 93. Global Neuroblastoma Chemotherapy Drugs Sales Market Share Forecast by Application (2023-2028)
Table 94. Global Neuroblastoma Chemotherapy Drugs Revenue Forecast by Application (2023-2028) & ($ Millions)
Table 95. Global Neuroblastoma Chemotherapy Drugs Revenue Market Share Forecast by Application (2023-2028)
Table 96. Baxter Healthcare Basic Information, Neuroblastoma Chemotherapy Drugs Manufacturing Base, Sales Area and Its Competitors
Table 97. Baxter Healthcare Neuroblastoma Chemotherapy Drugs Product Offered
Table 98. Baxter Healthcare Neuroblastoma Chemotherapy Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 99. Baxter Healthcare Main Business
Table 100. Baxter Healthcare Latest Developments
Table 101. Ingenus Pharmaceuticals Basic Information, Neuroblastoma Chemotherapy Drugs Manufacturing Base, Sales Area and Its Competitors
Table 102. Ingenus Pharmaceuticals Neuroblastoma Chemotherapy Drugs Product Offered
Table 103. Ingenus Pharmaceuticals Neuroblastoma Chemotherapy Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 104. Ingenus Pharmaceuticals Main Business
Table 105. Ingenus Pharmaceuticals Latest Developments
Table 106. ANI Pharmaceuticals Basic Information, Neuroblastoma Chemotherapy Drugs Manufacturing Base, Sales Area and Its Competitors
Table 107. ANI Pharmaceuticals Neuroblastoma Chemotherapy Drugs Product Offered
Table 108. ANI Pharmaceuticals Neuroblastoma Chemotherapy Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 109. ANI Pharmaceuticals Main Business
Table 110. ANI Pharmaceuticals Latest Developments
Table 111. Teva Pharmaceuticals Basic Information, Neuroblastoma Chemotherapy Drugs Manufacturing Base, Sales Area and Its Competitors
Table 112. Teva Pharmaceuticals Neuroblastoma Chemotherapy Drugs Product Offered
Table 113. Teva Pharmaceuticals Neuroblastoma Chemotherapy Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 114. Teva Pharmaceuticals Main Business
Table 115. Teva Pharmaceuticals Latest Developments
Table 116. Qilu Pharmaceutical Basic Information, Neuroblastoma Chemotherapy Drugs Manufacturing Base, Sales Area and Its Competitors
Table 117. Qilu Pharmaceutical Neuroblastoma Chemotherapy Drugs Product Offered
Table 118. Qilu Pharmaceutical Neuroblastoma Chemotherapy Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 119. Qilu Pharmaceutical Main Business
Table 120. Qilu Pharmaceutical Latest Developments
Table 121. Pfizer Basic Information, Neuroblastoma Chemotherapy Drugs Manufacturing Base, Sales Area and Its Competitors
Table 122. Pfizer Neuroblastoma Chemotherapy Drugs Product Offered
Table 123. Pfizer Neuroblastoma Chemotherapy Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 124. Pfizer Main Business
Table 125. Pfizer Latest Developments
Table 126. Hikma Pharmaceuticals Basic Information, Neuroblastoma Chemotherapy Drugs Manufacturing Base, Sales Area and Its Competitors
Table 127. Hikma Pharmaceuticals Neuroblastoma Chemotherapy Drugs Product Offered
Table 128. Hikma Pharmaceuticals Neuroblastoma Chemotherapy Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 129. Hikma Pharmaceuticals Main Business
Table 130. Hikma Pharmaceuticals Latest Developments
Table 131. Fresenius Kabi Basic Information, Neuroblastoma Chemotherapy Drugs Manufacturing Base, Sales Area and Its Competitors
Table 132. Fresenius Kabi Neuroblastoma Chemotherapy Drugs Product Offered
Table 133. Fresenius Kabi Neuroblastoma Chemotherapy Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 134. Fresenius Kabi Main Business
Table 135. Fresenius Kabi Latest Developments
Table 136. Accord Healthcare Basic Information, Neuroblastoma Chemotherapy Drugs Manufacturing Base, Sales Area and Its Competitors
Table 137. Accord Healthcare Neuroblastoma Chemotherapy Drugs Product Offered
Table 138. Accord Healthcare Neuroblastoma Chemotherapy Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 139. Accord Healthcare Main Business
Table 140. Accord Healthcare Latest Developments
Table 141. Viatris Basic Information, Neuroblastoma Chemotherapy Drugs Manufacturing Base, Sales Area and Its Competitors
Table 142. Viatris Neuroblastoma Chemotherapy Drugs Product Offered
Table 143. Viatris Neuroblastoma Chemotherapy Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 144. Viatris Main Business
Table 145. Viatris Latest Developments
List of Figures
Figure 1. Picture of Neuroblastoma Chemotherapy Drugs
Figure 2. Neuroblastoma Chemotherapy Drugs Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Neuroblastoma Chemotherapy Drugs Sales Growth Rate 2017-2028 (K Units)
Figure 7. Global Neuroblastoma Chemotherapy Drugs Revenue Growth Rate 2017-2028 ($ Millions)
Figure 8. Neuroblastoma Chemotherapy Drugs Sales by Region (2021 & 2028) & ($ millions)
Figure 9. Product Picture of Cyclophosphamide
Figure 10. Product Picture of Cisplatin or Carboplatin
Figure 11. Product Picture of Vincristine
Figure 12. Product Picture of Doxorubicin (Adriamycin)
Figure 13. Product Picture of Etoposide
Figure 14. Product Picture of Other
Figure 15. Global Neuroblastoma Chemotherapy Drugs Sales Market Share by Type in 2021
Figure 16. Global Neuroblastoma Chemotherapy Drugs Revenue Market Share by Type (2017-2022)
Figure 17. Neuroblastoma Chemotherapy Drugs Consumed in Hospital
Figure 18. Global Neuroblastoma Chemotherapy Drugs Market: Hospital (2017-2022) & (K Units)
Figure 19. Neuroblastoma Chemotherapy Drugs Consumed in Clinic
Figure 20. Global Neuroblastoma Chemotherapy Drugs Market: Clinic (2017-2022) & (K Units)
Figure 21. Neuroblastoma Chemotherapy Drugs Consumed in Other
Figure 22. Global Neuroblastoma Chemotherapy Drugs Market: Other (2017-2022) & (K Units)
Figure 23. Global Neuroblastoma Chemotherapy Drugs Sales Market Share by Application (2017-2022)
Figure 24. Global Neuroblastoma Chemotherapy Drugs Revenue Market Share by Application in 2021
Figure 25. Neuroblastoma Chemotherapy Drugs Revenue Market by Company in 2021 ($ Million)
Figure 26. Global Neuroblastoma Chemotherapy Drugs Revenue Market Share by Company in 2021
Figure 27. Global Neuroblastoma Chemotherapy Drugs Sales Market Share by Geographic Region (2017-2022)
Figure 28. Global Neuroblastoma Chemotherapy Drugs Revenue Market Share by Geographic Region in 2021
Figure 29. Global Neuroblastoma Chemotherapy Drugs Sales Market Share by Region (2017-2022)
Figure 30. Global Neuroblastoma Chemotherapy Drugs Revenue Market Share by Country/Region in 2021
Figure 31. Americas Neuroblastoma Chemotherapy Drugs Sales 2017-2022 (K Units)
Figure 32. Americas Neuroblastoma Chemotherapy Drugs Revenue 2017-2022 ($ Millions)
Figure 33. APAC Neuroblastoma Chemotherapy Drugs Sales 2017-2022 (K Units)
Figure 34. APAC Neuroblastoma Chemotherapy Drugs Revenue 2017-2022 ($ Millions)
Figure 35. Europe Neuroblastoma Chemotherapy Drugs Sales 2017-2022 (K Units)
Figure 36. Europe Neuroblastoma Chemotherapy Drugs Revenue 2017-2022 ($ Millions)
Figure 37. Middle East & Africa Neuroblastoma Chemotherapy Drugs Sales 2017-2022 (K Units)
Figure 38. Middle East & Africa Neuroblastoma Chemotherapy Drugs Revenue 2017-2022 ($ Millions)
Figure 39. Americas Neuroblastoma Chemotherapy Drugs Sales Market Share by Country in 2021
Figure 40. Americas Neuroblastoma Chemotherapy Drugs Revenue Market Share by Country in 2021
Figure 41. United States Neuroblastoma Chemotherapy Drugs Revenue Growth 2017-2022 ($ Millions)
Figure 42. Canada Neuroblastoma Chemotherapy Drugs Revenue Growth 2017-2022 ($ Millions)
Figure 43. Mexico Neuroblastoma Chemotherapy Drugs Revenue Growth 2017-2022 ($ Millions)
Figure 44. Brazil Neuroblastoma Chemotherapy Drugs Revenue Growth 2017-2022 ($ Millions)
Figure 45. APAC Neuroblastoma Chemotherapy Drugs Sales Market Share by Region in 2021
Figure 46. APAC Neuroblastoma Chemotherapy Drugs Revenue Market Share by Regions in 2021
Figure 47. China Neuroblastoma Chemotherapy Drugs Revenue Growth 2017-2022 ($ Millions)
Figure 48. Japan Neuroblastoma Chemotherapy Drugs Revenue Growth 2017-2022 ($ Millions)
Figure 49. South Korea Neuroblastoma Chemotherapy Drugs Revenue Growth 2017-2022 ($ Millions)
Figure 50. Southeast Asia Neuroblastoma Chemotherapy Drugs Revenue Growth 2017-2022 ($ Millions)
Figure 51. India Neuroblastoma Chemotherapy Drugs Revenue Growth 2017-2022 ($ Millions)
Figure 52. Australia Neuroblastoma Chemotherapy Drugs Revenue Growth 2017-2022 ($ Millions)
Figure 53. Europe Neuroblastoma Chemotherapy Drugs Sales Market Share by Country in 2021
Figure 54. Europe Neuroblastoma Chemotherapy Drugs Revenue Market Share by Country in 2021
Figure 55. Germany Neuroblastoma Chemotherapy Drugs Revenue Growth 2017-2022 ($ Millions)
Figure 56. France Neuroblastoma Chemotherapy Drugs Revenue Growth 2017-2022 ($ Millions)
Figure 57. UK Neuroblastoma Chemotherapy Drugs Revenue Growth 2017-2022 ($ Millions)
Figure 58. Italy Neuroblastoma Chemotherapy Drugs Revenue Growth 2017-2022 ($ Millions)
Figure 59. Russia Neuroblastoma Chemotherapy Drugs Revenue Growth 2017-2022 ($ Millions)
Figure 60. Middle East & Africa Neuroblastoma Chemotherapy Drugs Sales Market Share by Country in 2021
Figure 61. Middle East & Africa Neuroblastoma Chemotherapy Drugs Revenue Market Share by Country in 2021
Figure 62. Egypt Neuroblastoma Chemotherapy Drugs Revenue Growth 2017-2022 ($ Millions)
Figure 63. South Africa Neuroblastoma Chemotherapy Drugs Revenue Growth 2017-2022 ($ Millions)
Figure 64. Israel Neuroblastoma Chemotherapy Drugs Revenue Growth 2017-2022 ($ Millions)
Figure 65. Turkey Neuroblastoma Chemotherapy Drugs Revenue Growth 2017-2022 ($ Millions)
Figure 66. GCC Country Neuroblastoma Chemotherapy Drugs Revenue Growth 2017-2022 ($ Millions)
Figure 67. Manufacturing Cost Structure Analysis of Neuroblastoma Chemotherapy Drugs in 2021
Figure 68. Manufacturing Process Analysis of Neuroblastoma Chemotherapy Drugs
Figure 69. Industry Chain Structure of Neuroblastoma Chemotherapy Drugs
Figure 70. Channels of Distribution
Figure 71. Distributors Profiles
The global digital pathology market was valued at $3,323 million in 2016, and is expected to reach $8,668 million by 2023, registering a CAGR of 14.8% during the forecast period. Digital pathology is defined as an image-based information setting enabled b...
The global regenerative medicine market was valued at $5,444 million in 2016, and is estimated to reach $39,325 million by 2023, registering a CAGR of 32.2% from 2017 to 2023. Regenerative medicines are used to repair, replace, and regenerate tissues & organs that are affected owin...
The medical robotics and computer-assisted surgery is a combination of equipment, accessories, software, and services that aid in performing different functions, such as robotic minimally invasive and non-invasive radiosurgeries, rehabilitation therapies, and hospital & pharmacy automation. Surgical robotics...